経皮吸収型ドラッグデリバリーシステムの世界市場予測（～2023年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.1.1 SECONDARY DATA 20
2.1.1.1 Key Data from Secondary Sources 20
2.1.2 PRIMARY DATA 22
2.1.2.1 Key Data from Primary Sources 23
2.1.2.2 Key Industry Insights 24
2.2 MARKET SIZE ESTIMATION 24
2.2.1 MARKET DATA VALIDATION AND TRIANGULATION 26
2.3 ASSUMPTIONS FOR THE STUDY 27
3 EXECUTIVE SUMMARY 28
4 PREMIUM INSIGHTS 32
4.1 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET OVERVIEW 32
4.2 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 33
4.3 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE, 2018 34
4.4 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET: GEOGRAPHIC SNAPSHOT 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 36
5.2 MARKET DYNAMICS 36
5.2.1 DRIVERS 37
5.2.1.1 Increasing prevalence of chronic diseases 37
5.2.1.2 Technological advancements in transdermal drug delivery systems 37
5.2.2 RESTRAINTS 38
5.2.2.1 Drug failure and recalls of transdermal drug delivery systems 38
 
5.2.3 OPPORTUNITIES 38
5.2.3.1 Collaborations between pharmaceutical companies and drug delivery firms 38
5.2.3.2 Self-administration and home care drug delivery systems 39
5.2.4 CHALLENGES 39
5.2.4.1 Technical barriers related to skin irritation and permeability 39
6 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY TYPE 40
6.1 INTRODUCTION 41
6.2 TRANSDERMAL PATCHES 42
6.2.1 DRUG-IN-ADHESIVE PATCHES 42
6.2.2 MATRIX PATCHES 43
6.2.3 RESERVOIR MEMBRANE PATCHES 43
6.2.4 MICRONEEDLE PATCHES 43
6.3 TRANSDERMAL SEMISOLIDS 45
6.3.1 GELS 45
6.3.2 OINTMENTS 45
6.3.3 SPRAYS 46
7 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY APPLICATION 47
7.1 INTRODUCTION 48
7.2 PAIN MANAGEMENT 49
7.2.1 PAIN MANAGEMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET 49
7.3 HORMONAL APPLICATIONS 51
7.3.1 TESTOSTERONE REPLACEMENT THERAPY 52
7.3.1.1 Skin irritation, poor absorption of drugs, high costs, and the need for frequent dosing are factors limiting market growth 52
7.3.2 TRANSDERMAL ESTROGEN THERAPY 53
7.3.2.1 Growing use of transdermal contraceptive patches is likely to drive the market for transdermal estrogen therapy 53
7.4 CENTRAL NERVOUS SYSTEM DISORDERS 53
7.4.1 INCREASING INCIDENCE OF PARKINSON’S AND ALZHEIMER’S DISEASE TO DRIVE THE MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS 53
7.5 CARDIOVASCULAR DISEASES 55
7.5.1 AVAILABILITY OF ALTERNATIVE AND ADVANCED DRUG DELIVERY OPTIONS TO LIMIT MARKET GROWTH 55
7.6 OTHER APPLICATIONS 57
7.6.1 INCREASING DEMAND FOR ADVANCED TRANSDERMAL MICRONEEDLE PATCHES FOR DIABETES MANAGEMENT—A KEY MARKET DRIVER 57
 
8 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY END USER 59
8.1 INTRODUCTION 60
8.2 HOME CARE SETTINGS 61
8.3 HOSPITALS & CLINICS 62
9 TRANSDERMAL DRUG DELIVERY SYSTEMS MARKET, BY REGION 64
9.1 INTRODUCTION 65
9.2 NORTH AMERICA 67
9.2.1 US 70
9.2.1.1 Rising prevalence of targeted disease and development of technologically advanced transdermal drug delivery systems—key factors driving market growth 70
9.2.2 CANADA 72
9.2.2.1 Rising prevalence of chronic diseases and funding for the development of transdermal drug delivery systems to drive market growth 72
9.3 EUROPE 74
9.3.1 GERMANY 77
9.3.1.1 Growing focus of pharmaceutical companies in Germany on the development of transdermal products to drive market growth 77
9.3.2 UK 79
9.3.2.1 Increasing funding for the R&D of innovative transdermal technologies to drive market growth 79
9.3.3 FRANCE 81
9.3.3.1 Development of transdermal drug delivery systems by local players to support market growth 81
9.3.4 ROE 83
9.4 ASIA PACIFIC 85
9.4.1 JAPAN 88
9.4.1.1 Increasing number of product approvals and growing focus of local players on R&D of transdermal systems to support market growth 88
9.4.2 CHINA 91
9.4.2.1 Growing focus of major players in China towards the development of transdermal drug delivery systems to drive market growth 91
9.4.3 INDIA 92
9.4.3.1 Growing awareness among healthcare providers and patients and increasing focus on noninvasive methods of drug delivery to drive market growth 92
9.4.4 ROPAC 94
9.5 ROW 96
 
10 COMPETITIVE LANDSCAPE 99
10.1 OVERVIEW 99
10.2 MARKET SHARE ANALYSIS 100
10.3 MARKET SHARE ANALYSIS, BY APPLICATION 100
10.3.1 PAIN MANAGEMENT 100
10.3.2 HORMONAL APPLICATIONS 101
10.3.3 CENTRAL NERVOUS SYSTEM DISORDERS 101
10.3.4 CARDIOVASCULAR DISEASES 102
10.4 COMPETITIVE SCENARIO 102
10.4.1 PRODUCT LAUNCHES AND APPROVALS 102
10.4.2 EXPANSIONS 103
10.4.3 AGREEMENTS AND COLLABORATIONS 103
10.4.4 ACQUISITIONS 104
11 COMPANY PROFILES 105
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 HISAMITSU PHARMACEUTICAL CO., INC. 105
11.2 MYLAN N.V. 108
11.3 UCB S.A. 110
11.4 NOVARTIS AG 112
11.5 GLAXOSMITHKLINE PLC 114
11.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 116
11.7 JOHNSON & JOHNSON (J&J) 118
11.8 ENDO INTERNATIONAL, INC. 120
11.9 PURDUE PHARMA L.P. 122
11.10 LAVIPHARM 123
11.11 LEAD CHEMICALS CO., INC. 124
11.12 LUYE PHARMA GROUP 125
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
12 APPENDIX 127
12.1 DISCUSSION GUIDE 127
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 130
12.3 AVAILABLE CUSTOMIZATIONS 132
12.4 RELATED REPORTS 132
12.5 AUTHOR DETAILS 133